CNEN

Welcome to Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.!

Search

Copyright:  Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.!   京ICP备19006400号-1​     Powered by 300.cn

美科

Links:

A number of Class A Hospitals in China

2018年8月,九芝堂美科与北京天坛医院签订《干细胞临床研究基地共建协议》。双方就干细胞治疗疾病感兴趣的适应症上优先开展干细胞临床合作,并且天坛医院专家作为美科新药注册申请的“干细胞治疗脑卒中后遗症”及“干细胞治疗阿尔茨海默症”的主要研究者,双方共同开展药物临床试验。未来,双方将就干细胞药物的药效方面开展更多的研究,进一步开发干细胞在其他适应症上的应用。
Affiliate classification
没有此类产品
Details

A number of Class A Hospitals in China

In August 2018, Jiuzhitang Maker and Beijing Tiantan Hospital signed the “Co-establishment Agreement for Stem Cell Clinical Research Base”. Both parties will continue to advance the preclinical research work on stem cells, and Tiantan Hospital experts will act as the main principal investigator of the clinical trials "Stem cell treatment of stroke sequelae" and "Stem cell treatment of Alzheimer's disease". At present, the research base jointly built by both parties has been completed. In the future, more research will be carried out on the efficacy of stem cell drugs, and the application of other indications will be further developed.

 

首都医科大学附属北京天坛医院

 

The 2nd Affiliated Hospital of Harbin Medical University

With the lot area being 500,000 m2 and floor area being 530,000 m2, the 2nd Affiliated Hospital of Harbin Medical University has 1 outpatient department, 11 inpatient departments and 4 specialized hospitals dedicated to treatment of rheumatism, cardiovascular disorders, diseases involving the five sense organs and diabetes.

In May 2020, by signing a Cooperation Agreement, Jiuzhitang Maker and the 2nd Affiliated Hospital of Harbin Medical University agreed to jointly apply for a filed clinical study on stem cells with National Health Commission.

 

 

Corresponding parameter set not found, please add it in property template of background
暂未实现,敬请期待
暂未实现,敬请期待
Previous article